NorthStar Medical Radioisotopes and QSA Global have announced a multi-year strategic partnership focused on strengthening the supply chain for Actinium-225. This isotope is a key component in the development of targeted alpha therapies used in cancer treatment.
The agreement aims to ensure a more consistent and reliable supply of Actinium-225, addressing potential shortages and supporting the growing demand from the pharmaceutical and medical research sectors. Both companies are involved in different aspects of the radiopharmaceutical supply chain, and this collaboration seeks to leverage their respective capabilities.
Details regarding the specific contributions of each company or the financial terms of the partnership have not been fully disclosed. However, the stated objective is to enhance the availability of Actinium-225 for both clinical research and therapeutic applications, potentially impacting the accessibility of advanced cancer treatments.
